Myles David C.
SEC CIK 1831216 · EDGAR
BoughtSold
Companies
| Ticker | Company | Title | Holding | Bought | Sold | Trades | First | Last |
|---|---|---|---|---|---|---|---|---|
| OLMA | Olema Pharmaceuticals, Inc. | Chief DEVELOPMENT Off | 592.8K | — | $5.61M | 13 | 2021-12-10 | 2026-01-13 |
Most active insiders at OLMA, 12 months
| # | Insider | Title | Bought | Sold |
|---|---|---|---|---|
| 1 | CLARK IAN T | Dir | — | $7.87M |
| 2 | Zojwalla Naseem | Chief Medical Off | — | $7.53M |
| 3 | Myles David C. | CH. DISCOV, NON-CLIN DEV OFF | — | $4.66M |
| 4 | Kovacs Shane William Charles | CH. OPERATING, FINANCIAL OFF | — | $2.98M |
| 5 | Mitchell Shawnte | CLO | — | $951.5K |
| 6 | Harmon Cyrus | Dir | — | $743.8K |
| 7 | Austin Sasha Lu | VP of Fin, Ctrl | — | — |
| 8 | Bohen Sean | Pres, CEO, Dir | — | — |
| 9 | RAPPAPORT ANDREW | Dir | — | — |
Transactions 13
| X | Filed | Traded | Ticker | Company | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| DI | 2026-01-14 | 2026-01-12 | OLMA | Olema Pharmaceuticals, Inc. | Myles David C. | CH. DISCOV, NON-CLIN DEV OFF | S - Sale+OE | $28.34 | -10.0K | 144.8K | -6% | -$283.4K |
| DM | 2026-01-14 | 2026-01-13+ | OLMA | Olema Pharmaceuticals, Inc. | Myles David C. | CH. DISCOV, NON-CLIN DEV OFF | M - OptEx | $4.87 | +100.0K | 592.8K | +20% | +$487.0K |
| DM | 2026-01-14 | 2026-01-13+ | OLMA | Olema Pharmaceuticals, Inc. | Myles David C. | CH. DISCOV, NON-CLIN DEV OFF | S - Sale+OE | $28.24 | -100.0K | 542.8K | -16% | -$2.82M |
| 2025-12-23 | 2025-12-19 | OLMA | Olema Pharmaceuticals, Inc. | Myles David C. | CH. DISCOV, NON-CLIN DEV OFF | G - Gift | $0.00 | -9,000 | 542.9K | -2% | $0 | |
| M | 2025-12-23 | 2025-12-19 | OLMA | Olema Pharmaceuticals, Inc. | Myles David C. | CH. DISCOV, NON-CLIN DEV OFF | S - Sale | $30.46 | -51.0K | 601.7K | -8% | -$1.55M |
| M | 2024-12-11 | 2024-12-10+ | OLMA | Olema Pharmaceuticals, Inc. | Myles David C. | CH. DISCOV, NON-CLIN DEV OFF | S - Sale | $9.01 | -26.1K | 611.9K | -4% | -$234.9K |
| 2024-12-11 | 2024-12-09 | OLMA | Olema Pharmaceuticals, Inc. | Myles David C. | CH. DISCOV, NON-CLIN DEV OFF | A - Grant | $0.00 | +48.8K | 624.4K | +8% | $0 | |
| M | 2023-11-22 | 2023-11-21+ | OLMA | Olema Pharmaceuticals, Inc. | Myles David C. | CH. DISCOV, NON-CLIN DEV OFF | S - Sale | $14.40 | -13.6K | 574.1K | -2% | -$196.2K |
| 2023-11-22 | 2023-11-20 | OLMA | Olema Pharmaceuticals, Inc. | Myles David C. | CH. DISCOV, NON-CLIN DEV OFF | A - Grant | $0.00 | +26.2K | 587.7K | +5% | $0 | |
| 2023-11-13 | 2023-11-08 | OLMA | Olema Pharmaceuticals, Inc. | Myles David C. | CH. DISCOV, NON-CLIN DEV OFF | S - Sale | $17.61 | -200 | 561.3K | -0.0% | -$3,522 | |
| M | 2023-11-03 | 2023-11-01+ | OLMA | Olema Pharmaceuticals, Inc. | Myles David C. | CH. DISCOV, NON-CLIN DEV OFF | S - Sale | $15.26 | -10.5K | 561.5K | -2% | -$160.8K |
| 2023-09-21 | 2023-09-19 | OLMA | Olema Pharmaceuticals, Inc. | Myles David C. | CH. DISCOV, NON-CLIN DEV OFF | S - Sale | $12.67 | -20.0K | 572.0K | -3% | -$253.4K | |
| 2021-12-14 | 2021-12-10 | OLMA | Olema Pharmaceuticals, Inc. | Myles David C. | Chief DEVELOPMENT Off | S - Sale | $10.30 | -10.0K | 582.9K | -2% | -$103.0K |
Purchase Sale Sale after option exercise All abbreviations